Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NSC001 · 1 trial · 1 indication
Number of Adverse Events (AEs) between V1 (Baseline) -V5 (End of Treatment)
Number of Serious Adverse Events (SAEs) between V1 (Baseline) -V5 (End of Treatment)
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | 40 mg QD of NSC001 |
| Arm 2 | EXPERIMENTAL | 40 mg QD of NSC001 + 20 mg of Trospium |
| Arm 3 | PLACEBO_COMPARATOR | Placebo: with or without 20 mg of Trospium |
| Name | Type | Description |
|---|---|---|
| NSC001 | DRUG | rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor |
| Placebo | OTHER | matching placebo to NSC001 |
Inclusion Criteria: * Participants and competent trial partner/caregiver are willing and able to give signed informed consent for participation in the trial including compliance with the requirements and restrictions according to local regulations for the trial Informed Consent Form (ICF). Signed i...
Top 20 of 24 competitors
NSC001 is an investigational small molecule being developed for the treatment of mild to moderate Alzheimer's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and potential efficacy in patients with this condition.
NSC001 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical research on this investigational small molecule for Alzheimer's Disease, with the drug currently in Phase 1 development.
NSC001 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of NSC001 in patients with mild to moderate Alzheimer's Disease.
NSC001 is being evaluated in a single Phase 1 clinical trial registered as NCT06995573. This randomized, double-blind, placebo-controlled study is recruiting 90 participants aged 50 years and older with mild to moderate Alzheimer's Disease. The trial is being conducted at sites in Austria and Germany and is currently in the recruiting phase.
NSC001 is a small molecule being investigated for the treatment of Alzheimer's Disease. The specific molecular target of NSC001 has not been disclosed in available information. The ongoing Phase 1 trial is designed to explore the drug's safety, tolerability, and potential efficacy in patients with mild to moderate Alzheimer's Disease.